Cara Therapeutics (CARA) Set to Announce Earnings on Monday

Cara Therapeutics (NASDAQ:CARAGet Free Report) is scheduled to be releasing its earnings data after the market closes on Monday, March 4th. Analysts expect Cara Therapeutics to post earnings of ($0.58) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Cara Therapeutics Price Performance

CARA stock opened at $0.91 on Monday. The company has a fifty day moving average price of $0.62 and a 200 day moving average price of $1.31. Cara Therapeutics has a 12 month low of $0.50 and a 12 month high of $10.39. The company has a market cap of $49.42 million, a price-to-earnings ratio of -0.42 and a beta of 0.59.

Wall Street Analysts Forecast Growth

CARA has been the subject of a number of analyst reports. Needham & Company LLC cut their price objective on shares of Cara Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, January 22nd. HC Wainwright cut their price objective on shares of Cara Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, December 19th. Piper Sandler restated a “neutral” rating on shares of Cara Therapeutics in a research report on Tuesday, November 14th. Finally, StockNews.com upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Cara Therapeutics has an average rating of “Hold” and an average price target of $12.79.

Check Out Our Latest Report on CARA

Hedge Funds Weigh In On Cara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. grew its stake in shares of Cara Therapeutics by 27.7% during the 1st quarter. Federated Hermes Inc. now owns 6,009 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 1,302 shares during the period. Tower Research Capital LLC TRC grew its stake in Cara Therapeutics by 117.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,070 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 4,896 shares during the last quarter. Cetera Advisor Networks LLC acquired a new stake in Cara Therapeutics in the 2nd quarter valued at about $93,000. Two Sigma Securities LLC acquired a new stake in Cara Therapeutics in the 1st quarter valued at about $58,000. Finally, Profund Advisors LLC acquired a new stake in Cara Therapeutics in the 1st quarter valued at about $59,000. 68.04% of the stock is owned by institutional investors and hedge funds.

About Cara Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

See Also

Earnings History for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.